We're sunsetting PodQuest on 2025-07-28. Thank you for your support!
Export Podcast Subscriptions
back
#255 ‒ Latest therapeutics in CVD, APOE’s role in Alzheimer’s disease and CVD, familial hypercholesterolemia, and more | John Kastelein, M.D., Ph.D.
02:04:18
Share
2023/5/22
The Peter Attia Drive
AI Chapters
Transcribe
Chapters
What is Familial Hypercholesterolemia (FH)?
How do phenotype and genotype differ in FH?
What are the pathophysiological effects of FH mutations?
How is FH clinically presented and diagnosed?
Why don't all FH patients develop premature ASCVD?
What are the treatments and preventions for FH?
Is elevated LDL truly causal in cardiovascular disease?
What is the history and role of CETP inhibitors?
What is the thrifty gene hypothesis and its relevance to FH?
What is the potential of the latest CETP inhibitor, obicetrapib?
What promising results have been seen in obicetrapib's phase 3 trials?
How does the APOE4 allele increase Alzheimer’s risk?
What role does APOE play in cardiovascular disease?
What are the key takeaways and future prospects?
Shownotes
Transcript
No transcript made for this episode yet, you may request it for free.